Browse the evidence

Obesity promotes the onset of atrial fibrillation (AF) through several pathways.

Understanding these pathways can help in developing targeted interventions for AF in obese patients.

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.

LA-induced mitochondrial perturbations are linked with gut dysbiosis.

Addressing mitochondrial health may also improve gut microbiome balance.

Gastrointestinal side effects from tirzepatide are common but mild to moderate, with less than 5% treatment discontinuation.

Practitioners should be aware of potential mild gastrointestinal side effects when prescribing tirzepatide.

The distribution of protein intake (balanced vs unbalanced) did not influence myofibrillar protein synthesis rates.

The timing and distribution of protein intake may not be critical for maximizing muscle protein synthesis in young adults.

Sarcopenic diabetes is recognized as a distinct clinical condition that requires more awareness and research.

There is a need for increased focus on sarcopenic diabetes in clinical practice and research.

GLP-1RAs can cause gastrointestinal adverse events such as nausea, vomiting, and diarrhea.

Healthcare providers should monitor patients for gastrointestinal side effects when prescribing GLP-1RAs.

Significant weight loss induced by caloric restriction and metabolic and bariatric surgery (MBS) results in high turnover bone loss.

Practitioners should be aware that significant weight loss from caloric restriction and MBS can lead to increased bone loss.

Weight loss after metabolic and bariatric surgery (MBS) is associated with a substantial deterioration in bone microarchitecture and strength, increasing fracture risk.

Clinicians should monitor bone health closely in patients undergoing MBS due to increased fracture risk.

Significant weight loss induced by GLP-1 receptor agonists (GLP-1Ra) may result in accelerated bone turnover and bone loss.

Healthcare providers should consider the impact of GLP-1Ra on bone health when prescribing these medications.

Dulaglutide is associated with a significantly higher risk of overall hematologic malignancy (OR = 2.18, 95%CI = 1.14-4.19).

Clinicians should be cautious when prescribing dulaglutide due to its association with increased hematologic malignancy risk.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate notable cardiovascular benefits beyond glucose regulation in patients with coronary artery disease (CAD).

Practitioners should consider SGLT2i and GLP-1 RAs for cardiovascular protection in CAD patients.

GLP-1 receptor agonist patients demonstrated higher overall complication rates (20%) compared to controls (10%), though this was not statistically significant (p=0.47).

Clinicians should be aware of the potential for higher complication rates in patients using GLP-1 receptor agonists.

GLP-1 medicines may contribute to decreased cancer incidence.

Consider the potential cancer risk reduction when prescribing GLP-1 medicines.

Gastrointestinal side effects were most common, with Semaglutide showing the highest incidence.

Clinicians should be aware of the potential for gastrointestinal side effects, particularly with Semaglutide.

GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy.

Clinicians should monitor patients on GLP-1 RAs for signs of gastroparesis and intussusception.

Tirzepatide is preferred over semaglutide due to less reported side effects and enhanced benefits in promoting bone formation.

Tirzepatide may be a better option for patients needing obesity management with fewer side effects.

Obesity is associated with increased risk of cancer, accounting for approximately 10% of new cancer diagnoses annually in the US.

Healthcare practitioners should consider obesity as a significant risk factor for cancer in their patients.

Adverse events from semaglutide were generally mild to moderate gastrointestinal effects and occurred more frequently in the semaglutide group.

Clinicians should monitor for mild to moderate gastrointestinal side effects in patients treated with semaglutide.

Semaglutide (SEM) and tirzepatide (TIR) use was associated with greater annualized total hip (TH) bone loss in patients without diabetes mellitus (DM) compared to controls.

Practitioners should monitor bone health in patients using GLP-1 RAs, especially those without DM.

Total hip (TH) bone loss was comparable between GLP-1 RA users and controls among patients with diabetes mellitus (DM).

Bone health monitoring may be less critical for patients with DM using GLP-1 RAs.

Atherogenic dyslipidemias are a major contributor to ASCVD within the CKM framework.

Recognize and address dyslipidemias in patients with obesity to mitigate cardiovascular disease risk.

GLP-1 RA users had a higher incidence of delayed wound healing (18.5% versus 7.5%) compared to nonusers.

Practitioners should monitor GLP-1 RA users for delayed wound healing post-surgery.

GLP-1 RA users had lower seroma rates (4.9% versus 14.0%) compared to nonusers.

Practitioners may consider GLP-1 RAs for potentially reducing seroma formation post-surgery.